1 Biomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, University of Leuven, Kapucijnenvoer 35d, 3000 Leuven, Belgium.
2 CellCarta NV, 2610 Antwerp, Belgium.
3 Department of Pathology, AZ Sint-Maarten, 2800 Mechelen, Belgium.
4 Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institute, 171 64 Stockholm, Sweden.
5 Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, 171 76 Stockholm, Sweden.
6 Institute of Pathology, Philipps-University Marburg and University Hospital Marburg (UKGM), Baldingerstr. 1, 35043 Marburg, Germany.
7 Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, 94800 Villejuif, France.
8 Oncostat U1018, Inserm, Labeled Ligue Contre le Cancer, University Paris-Saclay, 94800 Villejuif, France.
9 Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
10 Department of Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
11 Department of Pathology, Section of Breast Pathology, Northwestern University, Chicago, IL 60611, USA.
12 Translational Medicine, Bristol-Myers Squibb, Princeton, NJ 08540, USA.
13 Oncology Clinical Development, Bristol-Myers Squibb, Princeton, NJ 08540, USA.
14 Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, Edinburgh EH4 2XR, UK.
15 Laboratory of Translational Cell & Tissue Research, Department of Imaging and Pathology, University of Leuven, 3000 Leuven, Belgium.
16 Department of Pathology, University Hospitals Leuven, 3000 Leuven, Belgium.
17 Department of Pathology, Erasmus Medical Center-Cancer Institute, 3015 GD Rotterdam, The Netherlands.
18 Department of Pathology, GZA-ZNA Hospitals, 2610 Antwerp, Belgium.
19 Division of Research, Peter Mac Callum Cancer Centre, Melbourne, VIC 300, Australia.
Increasing data suggests that an intact immune system is required for improvedoutcomes in patients with Human Epidermal Growth Factor Receptor 2 (HER2+) and Triple Negative Breast Cancer (TNBC) [...].
Publication types
Editorial
Grants and funding
The training and EQC-platform have been supported by the Breast Cancer Research Foundation and Bristol-Myers Squib (CW3199227).